NO20052153L - Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer. - Google Patents
Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.Info
- Publication number
- NO20052153L NO20052153L NO20052153A NO20052153A NO20052153L NO 20052153 L NO20052153 L NO 20052153L NO 20052153 A NO20052153 A NO 20052153A NO 20052153 A NO20052153 A NO 20052153A NO 20052153 L NO20052153 L NO 20052153L
- Authority
- NO
- Norway
- Prior art keywords
- piperazine
- neurological diseases
- piperidine derivatives
- treatment
- treating
- Prior art date
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title abstract 4
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- 150000003053 piperidines Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 210000005036 nerve Anatomy 0.000 abstract 2
- 230000003961 neuronal insult Effects 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41613402P | 2002-10-03 | 2002-10-03 | |
| PCT/US2003/031080 WO2004031148A1 (en) | 2002-10-03 | 2003-10-02 | Piperazine and piperidine derivatives for treatment of neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20052153L true NO20052153L (no) | 2005-05-31 |
Family
ID=32069937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052153A NO20052153L (no) | 2002-10-03 | 2005-05-02 | Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040180880A1 (de) |
| EP (1) | EP1546103B1 (de) |
| JP (1) | JP2006504717A (de) |
| KR (1) | KR20050047132A (de) |
| CN (1) | CN100395236C (de) |
| AT (1) | ATE425967T1 (de) |
| AU (1) | AU2003299145A1 (de) |
| CA (1) | CA2500672A1 (de) |
| DE (1) | DE60326742D1 (de) |
| ES (1) | ES2324293T3 (de) |
| MX (1) | MXPA05003471A (de) |
| NO (1) | NO20052153L (de) |
| PL (1) | PL376149A1 (de) |
| RU (1) | RU2005113247A (de) |
| TW (1) | TW200533653A (de) |
| WO (1) | WO2004031148A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393656B2 (en) * | 2001-07-10 | 2008-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for risk stratification |
| GB0508319D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
| WO2007018459A1 (en) * | 2005-08-08 | 2007-02-15 | Astrazeneca Ab | Therapeutic agents |
| US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
| EP2419413B1 (de) * | 2009-04-16 | 2016-11-23 | Takeda Pharmaceutical Company Limited | Unter anderem zur prophylaxe oder behandlung von diabetes geeignete derivate von n-acyl-n'-phenylpiperazin |
| RU2486918C1 (ru) * | 2011-10-25 | 2013-07-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ стимулирования восстановления периферической иннервации тканей с помощью векторных конструкций |
| UA122423C2 (uk) | 2015-11-02 | 2020-11-10 | Янссен Фармацевтика Нв | [1,2,4]ТРИАЗОЛО[1,5-a]ПІРИМІДИН-7-ІЛЬНА СПОЛУКА |
| UA125302C2 (uk) | 2016-11-02 | 2022-02-16 | Янссен Фармацевтика Нв | Похідні [1,2,4]триазоло[1,5-a]піримідину як інгібітори pde2 |
| KR20190071721A (ko) | 2016-11-02 | 2019-06-24 | 얀센 파마슈티카 엔.브이. | Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물 |
| MA46690A (fr) | 2016-11-02 | 2019-09-11 | Janssen Pharmaceutica Nv | Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2597100A1 (fr) * | 1986-01-21 | 1987-10-16 | Nippon Shinyaku Co Ltd | Derives du pyroglutamide |
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| US5780484A (en) * | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
| US5811434A (en) * | 1996-11-13 | 1998-09-22 | Vertex Pharmacueticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5721256A (en) | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
| SG129998A1 (en) * | 1997-08-29 | 2007-03-20 | Vertex Pharma | Compounds possessing neuronal activity |
| US6331537B1 (en) * | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| US6264991B1 (en) * | 1998-08-18 | 2001-07-24 | Southern Research Institute | Compositions and methods for treating intracellular infections |
| HRP20020737A2 (en) * | 2000-02-11 | 2005-10-31 | Vertex Pharmaceuticals Incorporated | Piperazine and piperidine derivatives for treatment or prevention of nruronal damage |
| US20040034019A1 (en) * | 2002-08-08 | 2004-02-19 | Ronald Tomlinson | Piperazine and piperidine derivatives |
-
2003
- 2003-10-02 MX MXPA05003471A patent/MXPA05003471A/es not_active Application Discontinuation
- 2003-10-02 CN CNB2003801041723A patent/CN100395236C/zh not_active Expired - Fee Related
- 2003-10-02 ES ES03756899T patent/ES2324293T3/es not_active Expired - Lifetime
- 2003-10-02 RU RU2005113247/04A patent/RU2005113247A/ru not_active Application Discontinuation
- 2003-10-02 AU AU2003299145A patent/AU2003299145A1/en not_active Abandoned
- 2003-10-02 AT AT03756899T patent/ATE425967T1/de not_active IP Right Cessation
- 2003-10-02 DE DE60326742T patent/DE60326742D1/de not_active Expired - Lifetime
- 2003-10-02 KR KR1020057005779A patent/KR20050047132A/ko not_active Withdrawn
- 2003-10-02 WO PCT/US2003/031080 patent/WO2004031148A1/en not_active Ceased
- 2003-10-02 PL PL03376149A patent/PL376149A1/xx not_active Application Discontinuation
- 2003-10-02 CA CA002500672A patent/CA2500672A1/en not_active Abandoned
- 2003-10-02 EP EP03756899A patent/EP1546103B1/de not_active Expired - Lifetime
- 2003-10-02 JP JP2004541991A patent/JP2006504717A/ja active Pending
- 2003-10-02 US US10/677,631 patent/US20040180880A1/en not_active Abandoned
-
2004
- 2004-04-05 TW TW093109385A patent/TW200533653A/zh unknown
-
2005
- 2005-05-02 NO NO20052153A patent/NO20052153L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05003471A (es) | 2005-07-01 |
| ATE425967T1 (de) | 2009-04-15 |
| JP2006504717A (ja) | 2006-02-09 |
| ES2324293T3 (es) | 2009-08-04 |
| CN1717390A (zh) | 2006-01-04 |
| TW200533653A (en) | 2005-10-16 |
| PL376149A1 (en) | 2005-12-27 |
| CA2500672A1 (en) | 2004-04-15 |
| EP1546103A1 (de) | 2005-06-29 |
| AU2003299145A1 (en) | 2004-04-23 |
| KR20050047132A (ko) | 2005-05-19 |
| CN100395236C (zh) | 2008-06-18 |
| WO2004031148A1 (en) | 2004-04-15 |
| US20040180880A1 (en) | 2004-09-16 |
| RU2005113247A (ru) | 2006-01-20 |
| DE60326742D1 (de) | 2009-04-30 |
| EP1546103B1 (de) | 2009-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2002002596A0 (en) | Piperazine and piperidine derivatives. | |
| TW200510334A (en) | Preraration and use of aryl alkyl acid derivatives for the treatment of obesity | |
| ATE362363T1 (de) | Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden | |
| DE60026155D1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
| ATE381935T1 (de) | Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen | |
| GEP20084420B (en) | Use of imidazole compounds for the treatment of neurodegenerative disorders | |
| TNSN05045A1 (en) | Indole or benzimidazole derivatives for modulating ikappab kinase | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| DE60029799D1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
| DE60112766D1 (de) | Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen | |
| ATE336996T1 (de) | Verwendung von flavonoid-derivaten zur behandlung von atopischem ekzem | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| DE602007011975D1 (de) | Thiadiazolderivate zur behandlung neurodegenerativer krankheiten | |
| MXPA04007031A (es) | Derivados benzofurano y benzotiofeno utiles en el tratamiento de desordenes hiper-proliferativos. | |
| PL376149A1 (en) | Piperazine and piperidine derivatives for treatment of neurological diseases | |
| DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| DE602005015697D1 (de) | Te zur behandlung von alzheimer-krankheit | |
| ATE380551T1 (de) | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson | |
| ATE482217T1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
| DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
| ATE350034T1 (de) | Verwendung von epothilone zur behandlung hyperparathyreoidismus | |
| MY141048A (en) | Morpholine derivatives as norepinephrine reuptake inhibitors | |
| DE10391491D2 (de) | Verwendung von Pyrimidinnukleotiden zur Behandlung von Schädigungen des peripheren Nervensystems | |
| ATE427754T1 (de) | Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |